First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Purpose: LV305 is a modified, third-generation, nonreplicating, integration-deficient lentivirus-based vector designed to selectively transduce dendritic cells in vivo. LV305 induces expression of the New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1) cancer testis antigen in dendritic cells, promoting immune responses against NY-ESO-1–expressing tumors. This phase I study evaluated the safety, immunogenicity, and preliminary efficacy of LV305 in patients with sarcoma or other solid tumors. Patients and Methods: Adults with previously treated, advanced, NY-ESO-1–positive solid tumors and limited tumor burden were eligible. LV305 was administered every 3 weeks by intradermal injection in four dose cohorts (Cohort 1: 108 vector genomes (vg) x 3 doses; Cohorts 1A, 2, and 3: 108 vg, 109 vg, 1010 vg x 4 doses). Results: Thirty-nine patients were enrolled: 3 patients each in Cohorts 1, 1A, and 2, and 30 patients in Cohort 3. No dose-limiting toxicities were observed. Tumor types included sarcoma (n = 24), ovarian (n = 8), melanoma (n = 6), and lung cancer (n = 1). All treatment-related adverse events were grade 1 or 2. Common treatment-related adverse events were fatigue (49%), injection site reactions (46%), and myalgia (21%). The disease control rate was 56.4% in all patients and 62.5% in sarcoma patients. One patient with synovial sarcoma achieved a partial response lasting >36 months. Anti–NY-ESO-1-specific CD4+ and/or CD8+ T cells were induced in 57% of evaluable sarcoma patients. Induction of an anti–NY-ESO-1 immune response was associated with improved 1-year survival in an exploratory analysis. Conclusions: This first-in-class, first-in-human study of LV305 demonstrated a favorable safety profile, induction of antigen-specific responses, and potential clinical activity in patients with advanced cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive assessment of T-cell receptor β-chain diversity in αβ T cells
Robins, H. S., Campregher, P. V., Srivastava, S. K., Wacher, A., Turtle, C. J., Kahsai, O., Riddell, S. R., Warren, E. H., & Carlson, C. S. (2009) · Blood · doi:10.1182/blood-2009-04-217604 · Cited by 1,122
Nishino, M., Giobbie-Hurder, A., Gargano, M., Suda, M., Ramaiya, N. H., & Hodi, F. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0895 · Cited by 522 · cited 1×
“Tumor response was assessed by the investigator using irRC (13, 14) modified to incorporate RECIST v 1.”
MethodAlbershardt, T. C., Campbell, D. J., Parsons, A. J., Slough, M. M., ter Meulen, J., & Berglund, P. (2016) · Molecular Therapy - Oncolytics · doi:10.1038/mto.2016.10 · Cited by 38 · cited 1×
“In preclinical studies, a single immunization with LV305 transduced DCs in vivo, generated multifunctional CD8 T-cell responses, and controlled the growth of NYESO-1–expressing murine tumors (7).”
BackgroundOdegard, J. M., Kelley-Clarke, B., Tareen, S. U., Campbell, D. J., Flynn, P. A., Nicolai, C. J., Slough, M. M., Vin, C. D., McGowan, P. J., Nelson, L. T., et al. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000067 · Cited by 26
Cited by
Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma
Baba, Y., Nomoto, D., Okadome, K., Ishimoto, T., Iwatsuki, M., Miyamoto, Y., Yoshida, N., & Baba, H. (2020) · Cancer Science · doi:10.1111/cas.14541 · Cited by 279
The old and the new: Prospects for non-integrating lentiviral vector technology
Apolonia, L. (2020) · Viruses · doi:10.3390/v12101103 · Cited by 58
Cancer testis antigens in sarcoma: Expression, function and immunotherapeutic application
Wei, R., Dean, D. C., Thanindratarn, P., Hornicek, F. J., Guo, W., & Duan, Z. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.10.024 · Cited by 48
Leleux, J. A., Albershardt, T. C., Parsons, A. J., ter Meulen, J., & Berglund, P. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.08.003 · Cited by 5
Metadata
- Authors
- Somaiah, N., Block, M. S., Kim, J. W., Shapiro, G. I., Do, K. T., Hwu, P., Eder, J. P., Jones, R. L., Lu, H., ter Meulen, J. H., Bohac, C., Chen, M., Hsu, F. J., Gnjatic, S., & Pollack, S. M.
- Venue
- Clinical Cancer Research
- Published
- 2019-10-01
- Volume
- 25
- Issue
- 19
- Pages
- 5808-5817
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2952820297
- Cited by
- 87
- References
- 4
- FWCI
- 4.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-19-1025
- The paper
- Somaiah, N., Block, M. S., Kim, J. W., Shapiro, G. I., Do, K. T., Hwu, P., Eder, J. P., Jones, R. L., Lu, H., ter Meulen, J. H., Bohac, C., Chen, M., Hsu, F. J., Gnjatic, S., & Pollack, S. M. (2019). First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-19-1025
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.